{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,7]],"date-time":"2026-10-07T15:01:33Z","timestamp":1791385293298,"version":"4.3.3"},"reference-count":97,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2024,2,1]],"date-time":"2024-02-01T00:00:00Z","timestamp":1706745600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,2,1]],"date-time":"2024-02-01T00:00:00Z","timestamp":1706745600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2024,2,1]],"date-time":"2024-02-01T00:00:00Z","timestamp":1706745600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2024,2,1]],"date-time":"2024-02-01T00:00:00Z","timestamp":1706745600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2024,2,1]],"date-time":"2024-02-01T00:00:00Z","timestamp":1706745600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2024,2,1]],"date-time":"2024-02-01T00:00:00Z","timestamp":1706745600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2024,2,1]],"date-time":"2024-02-01T00:00:00Z","timestamp":1706745600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["clinicalkey.fr","clinicalkey.jp","clinicalkey.com.au","clinicalkey.es","clinicalkey.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Psychiatric Research"],"published-print":{"date-parts":[[2024,2]]},"DOI":"10.1016\/j.jpsychires.2023.11.042","type":"journal-article","created":{"date-parts":[[2023,12,2]],"date-time":"2023-12-02T22:19:38Z","timestamp":1701555578000},"page":"65-72","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":10,"special_numbering":"C","title":["Revisiting benzodiazepines (GABA Enhancers):A transdiagnostic and precision medicine approach"],"prefix":"10.1016","volume":"170","author":[{"given":"Stefano","family":"Pallanti","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joseph","family":"Zohar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Siegfried","family":"Kasper","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hans-J\u00fcrgen","family":"M\u00f6ller","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eric","family":"Hollander","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"1","key":"10.1016\/j.jpsychires.2023.11.042_bib1","doi-asserted-by":"crossref","first-page":"66","DOI":"10.1002\/da.20220","article-title":"HPA axis activity in patients with panic disorder: review and synthesis of four studies","volume":"24","author":"Abelson","year":"2007","journal-title":"Depress. Anxiety"},{"issue":"1","key":"10.1016\/j.jpsychires.2023.11.042_bib2","doi-asserted-by":"crossref","first-page":"566","DOI":"10.1186\/s12889-019-6933-8","article-title":"Prevalence of prescribed benzodiazepine long-term use in the French general population according to sociodemographic and clinical factors: findings from the CONSTANCES cohort","volume":"19","author":"Airagnes","year":"2019","journal-title":"BMC Publ. Health"},{"issue":"12","key":"10.1016\/j.jpsychires.2023.11.042_bib3","doi-asserted-by":"crossref","first-page":"1096","DOI":"10.1177\/0004867414548902","article-title":"Benzodiazepine use and aggressive behaviour: a systematic review","volume":"48","author":"Albrecht","year":"2014","journal-title":"Aust. N. Z. J. Psychiatr."},{"key":"10.1016\/j.jpsychires.2023.11.042_bib4","series-title":"Diagnostic and Statistical Manual of Mental Disorders","year":"2013"},{"key":"10.1016\/j.jpsychires.2023.11.042_bib5","series-title":"APA Releases Diagnostic and Statistical Manual of Mental Disorders, Fifth Edition, Text Revision (DSM-5- TR)","year":"2022"},{"key":"10.1016\/j.jpsychires.2023.11.042_bib6","series-title":"Public Policy Statement: Definition of Addiction","author":"American Society of Addiction Medicine (Asam)","year":"2011"},{"issue":"3","key":"10.1016\/j.jpsychires.2023.11.042_bib7","first-page":"CD011481","article-title":"Pharmacological interventions for benzodiazepine discontinuation in chronic benzodiazepine users","volume":"3","author":"Baandrup","year":"2018","journal-title":"Cochrane Database Syst. Rev."},{"issue":"10","key":"10.1016\/j.jpsychires.2023.11.042_bib8","doi-asserted-by":"crossref","first-page":"2591","DOI":"10.1111\/add.15853","article-title":"Comparative efficacy and safety of pharmacotherapies for alcohol withdrawal: a systematic review and network meta-analysis","volume":"117","author":"Bahji","year":"2022","journal-title":"Addiction"},{"issue":"5","key":"10.1016\/j.jpsychires.2023.11.042_bib9","doi-asserted-by":"crossref","first-page":"1472","DOI":"10.1111\/add.15695","article-title":"Clinical management of withdrawal from benzodiazepine anxiolytic and hypnotic medications","volume":"117","author":"Baldwin","year":"2022","journal-title":"Addiction"},{"issue":"5","key":"10.1016\/j.jpsychires.2023.11.042_bib10","doi-asserted-by":"crossref","first-page":"291","DOI":"10.1159\/000525207","article-title":"Who's afraid of benzodiazepines?","volume":"91","author":"Balon","year":"2022","journal-title":"Psychother. Psychosom."},{"issue":"4","key":"10.1016\/j.jpsychires.2023.11.042_bib11","doi-asserted-by":"crossref","first-page":"193","DOI":"10.1159\/000489538","article-title":"International Task Force on benzodiazepines","volume":"87","author":"Balon","year":"2018","journal-title":"Psychother. Psychosom."},{"issue":"3","key":"10.1016\/j.jpsychires.2023.11.042_bib12","doi-asserted-by":"crossref","first-page":"327","DOI":"10.31887\/DCNS.2015.17.3\/bbandelow","article-title":"Epidemiology of anxiety disorders in the 21st century","volume":"17","author":"Bandelow","year":"2015","journal-title":"Dialogues Clin. Neurosci."},{"issue":"2","key":"10.1016\/j.jpsychires.2023.11.042_bib13","doi-asserted-by":"crossref","first-page":"79","DOI":"10.1080\/15622975.2022.2086295","article-title":"World Federation of Societies of Biological Psychiatry (WFSBP) guidelines for treatment of anxiety, obsessive-compulsive and posttraumatic stress disorders - version 3. Part I: anxiety disorders","volume":"24","author":"Bandelow","year":"2023","journal-title":"World J. Biol. Psychiatr."},{"key":"10.1016\/j.jpsychires.2023.11.042_bib14","first-page":"12","article-title":"Treatment of dystonia and tics","volume":"2","author":"Bellows","year":"2019","journal-title":"Clin Park Relat Disord"},{"issue":"2","key":"10.1016\/j.jpsychires.2023.11.042_bib15","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1159\/000486696","article-title":"Benzodiazepines as a monotherapy in depressive disorders: a systematic review","volume":"87","author":"Benasi","year":"2018","journal-title":"Psychother. Psychosom."},{"key":"10.1016\/j.jpsychires.2023.11.042_bib16","doi-asserted-by":"crossref","first-page":"g5205","DOI":"10.1136\/bmj.g5205","article-title":"Benzodiazepine use and risk of Alzheimer's disease: case-control study","volume":"349","author":"Billioti de Gage","year":"2014","journal-title":"BMJ"},{"issue":"4","key":"10.1016\/j.jpsychires.2023.11.042_bib17","doi-asserted-by":"crossref","first-page":"301","DOI":"10.1016\/j.eurpsy.2010.12.004","article-title":"Pregabalin for the discontinuation of long-term benzodiazepines use: an assessment of its effectiveness in daily clinical practice","volume":"27","author":"Bobes","year":"2012","journal-title":"Eur. Psychiatr."},{"issue":"2","key":"10.1016\/j.jpsychires.2023.11.042_bib18","first-page":"1","article-title":"The GABAA receptor and benzodiazepine acceptor site","volume":"5","author":"Bourin","year":"2018","journal-title":"SOJ Pharmacy and Pharmaceutical Sciences"},{"issue":"5","key":"10.1016\/j.jpsychires.2023.11.042_bib19","doi-asserted-by":"crossref","first-page":"1119","DOI":"10.1016\/j.neuron.2015.03.042","article-title":"The GABAA receptor as a therapeutic target for neurodevelopmental disorders","volume":"86","author":"Braat","year":"2015","journal-title":"Neuron"},{"issue":"6","key":"10.1016\/j.jpsychires.2023.11.042_bib20","doi-asserted-by":"crossref","first-page":"3192","DOI":"10.1073\/pnas.1906369117","article-title":"GABA-mediated tonic inhibition differentially modulates gain in functional subtypes of cortical interneurons","volume":"117","author":"Bryson","year":"2020","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"issue":"2","key":"10.1016\/j.jpsychires.2023.11.042_bib21","doi-asserted-by":"crossref","first-page":"149","DOI":"10.31887\/DCNS.2012.14.2\/ebui","article-title":"Pharmacological approaches to the treatment of complicated grief: rationale and a brief review of the literature","volume":"14","author":"Bui","year":"2012","journal-title":"Dialogues Clin. Neurosci."},{"issue":"7","key":"10.1016\/j.jpsychires.2023.11.042_bib22","doi-asserted-by":"crossref","first-page":"428","DOI":"10.1038\/s41582-022-00664-3","article-title":"Why won't it stop? The dynamics of benzodiazepine resistance in status epilepticus [published correction appears in Nat Rev Neurol","volume":"18","author":"Burman","year":"2022","journal-title":"Nat. Rev. Neurol."},{"issue":"4","key":"10.1016\/j.jpsychires.2023.11.042_bib23","doi-asserted-by":"crossref","first-page":"449","DOI":"10.1177\/02698811221080464","article-title":"To BDZ or not to BDZ? That is the question! Is there reliable scientific evidence for or against using benzodiazepines in the aftermath of potentially traumatic events for the prevention of PTSD? A systematic review and meta-analysis","volume":"36","author":"Campos","year":"2022","journal-title":"J. Psychopharmacol."},{"issue":"19","key":"10.1016\/j.jpsychires.2023.11.042_bib24","doi-asserted-by":"crossref","DOI":"10.3390\/ijerph181910222","article-title":"Cognitive behavioral therapy and acceptance and commitment therapy for the discontinuation of long-term benzodiazepine use in insomnia and anxiety disorders","volume":"18","author":"Chapoutot","year":"2021","journal-title":"Int. J. Environ. Res. Publ. Health"},{"issue":"5","key":"10.1016\/j.jpsychires.2023.11.042_bib25","doi-asserted-by":"crossref","first-page":"283","DOI":"10.1159\/000506868","article-title":"Acute and persistent withdrawal syndromes following discontinuation of psychotropic medications","volume":"89","author":"Cosci","year":"2020","journal-title":"Psychother. Psychosom."},{"issue":"1","key":"10.1016\/j.jpsychires.2023.11.042_bib26","doi-asserted-by":"crossref","first-page":"22","DOI":"10.1159\/000367913","article-title":"Mood and anxiety disorders as early manifestations of medical illness: a systematic review","volume":"84","author":"Cosci","year":"2015","journal-title":"Psychother. Psychosom."},{"issue":"10312","key":"10.1016\/j.jpsychires.2023.11.042_bib27","doi-asserted-by":"crossref","first-page":"1700","DOI":"10.1016\/S0140-6736(21)02143-7","article-title":"Global prevalence and burden of depressive and anxiety disorders in 204 countries and territories in 2020 due to the COVID-19 pandemic","volume":"398","year":"2021","journal-title":"Lancet"},{"issue":"2","key":"10.1016\/j.jpsychires.2023.11.042_bib28","doi-asserted-by":"crossref","first-page":"107","DOI":"10.31887\/DCNS.2017.19.2\/macrocq","article-title":"The history of generalized anxiety disorder as a diagnostic category","volume":"19","author":"Crocq","year":"2017","journal-title":"Dialogues Clin. Neurosci."},{"issue":"10347","key":"10.1016\/j.jpsychires.2023.11.042_bib29","doi-asserted-by":"crossref","first-page":"170","DOI":"10.1016\/S0140-6736(22)00878-9","article-title":"Comparative effects of pharmacological interventions for the acute and long-term management of insomnia disorder in adults: a systematic review and network meta-analysis","volume":"400","author":"De Crescenzo","year":"2022","journal-title":"Lancet"},{"key":"10.1016\/j.jpsychires.2023.11.042_bib30","first-page":"61","article-title":"Psychotropic dosing and monitoring guidelines","volume":"13","author":"DeBattista","year":"2006","journal-title":"Prim. Psychiatr."},{"issue":"6","key":"10.1016\/j.jpsychires.2023.11.042_bib31","doi-asserted-by":"crossref","first-page":"1526","DOI":"10.1007\/s11096-019-00915-2","article-title":"Outpatient benzodiazepine utilization in Croatia: drug use or misuse","volume":"41","author":"Dela\u0161 A\u017edaji\u0107","year":"2019","journal-title":"Int. J. Clin. Pharm."},{"key":"10.1016\/j.jpsychires.2023.11.042_bib32","series-title":"Diazepam. in: StatPearls. Treasure Island (FL)","author":"Dhaliwal","year":"2022"},{"issue":"12","key":"10.1016\/j.jpsychires.2023.11.042_bib33","doi-asserted-by":"crossref","first-page":"1960","DOI":"10.1016\/j.euroneuro.2016.10.005","article-title":"Pharmacological treatment strategies in unipolar depression in European tertiary psychiatric treatment centers - a pharmacoepidemiological cross-sectional multicenter study","volume":"26","author":"Dold","year":"2016","journal-title":"Eur. Neuropsychopharmacol"},{"issue":"5","key":"10.1016\/j.jpsychires.2023.11.042_bib34","doi-asserted-by":"crossref","first-page":"307","DOI":"10.1159\/000524400","article-title":"Benzodiazepines remain important therapeutic options in psychiatric practice","volume":"91","author":"Dubovsky","year":"2022","journal-title":"Psychother. Psychosom."},{"key":"10.1016\/j.jpsychires.2023.11.042_bib35","doi-asserted-by":"crossref","DOI":"10.1016\/j.drugalcdep.2021.108985","article-title":"Tolerance and dependence following chronic alprazolam treatment in rhesus monkeys: role of GABAAreceptor subtypes","volume":"228","author":"Duke","year":"2021","journal-title":"Drug Alcohol Depend."},{"key":"10.1016\/j.jpsychires.2023.11.042_bib36","doi-asserted-by":"crossref","DOI":"10.3389\/fpsyt.2021.699740","article-title":"Brexanolone, a GABAA modulator, in the treatment of postpartum depression in adults: a comprehensive review","volume":"12","author":"Edinoff","year":"2021","journal-title":"Front. Psychiatr."},{"issue":"4","key":"10.1016\/j.jpsychires.2023.11.042_bib37","doi-asserted-by":"crossref","first-page":"570","DOI":"10.3390\/neurolint13040057","article-title":"Catatonia: clinical overview of the diagnosis, treatment, and clinical challenges","volume":"13","author":"Edinoff","year":"2021","journal-title":"Neurol. Int."},{"key":"10.1016\/j.jpsychires.2023.11.042_bib38","doi-asserted-by":"crossref","first-page":"118","DOI":"10.1016\/j.neubiorev.2019.06.007","article-title":"Transcranial electrical and magnetic stimulation (tES and TMS) for addiction medicine: a consensus paper on the present state of the science and the road ahead","volume":"104","author":"Ekhtiari","year":"2019","journal-title":"Neurosci. Biobehav. Rev."},{"issue":"35","key":"10.1016\/j.jpsychires.2023.11.042_bib39","doi-asserted-by":"crossref","first-page":"5663","DOI":"10.2174\/138161212803530907","article-title":"The role of life events and HPA axis in anxiety disorders: a review","volume":"18","author":"Faravelli","year":"2012","journal-title":"Curr. Pharmaceut. Des."},{"issue":"7","key":"10.1016\/j.jpsychires.2023.11.042_bib40","doi-asserted-by":"crossref","first-page":"1109","DOI":"10.1007\/s00702-020-02285-w","article-title":"Adult attention-deficit\/hyperactivity disorder symptoms, cognitive dysfunction and quality of life in high-dose use of benzodiazepine and Z-drug","volume":"128","author":"Federico","year":"2021","journal-title":"J. Neural. Transm."},{"issue":"7","key":"10.1016\/j.jpsychires.2023.11.042_bib41","doi-asserted-by":"crossref","first-page":"737","DOI":"10.1080\/10715762.2018.1475733","article-title":"The role of oxidative stress in anxiety disorder: cause or consequence?","volume":"52","author":"Fedoce","year":"2018","journal-title":"Free Radic. Res."},{"issue":"4","key":"10.1016\/j.jpsychires.2023.11.042_bib42","doi-asserted-by":"crossref","first-page":"881","DOI":"10.1016\/0306-4522(93)90582-Z","article-title":"Neuron-specific expression of GABAA-receptor subtypes: differential association of the alpha 1- and alpha 3-subunits with serotonergic and GABAergic neurons","volume":"54","author":"Gao","year":"1993","journal-title":"Neuroscience"},{"issue":"9","key":"10.1016\/j.jpsychires.2023.11.042_bib43","first-page":"390","article-title":"Treatment of recent trauma survivors with benzodiazepines: a prospective study","volume":"57","author":"Gelpin","year":"1996","journal-title":"J. Clin. Psychiatry"},{"issue":"8","key":"10.1016\/j.jpsychires.2023.11.042_bib44","doi-asserted-by":"crossref","first-page":"883","DOI":"10.1080\/14656566.2018.1472767","article-title":"Comparing the efficacy of benzodiazepines and serotonergic anti-depressants for adults with generalized anxiety disorder: a meta-analytic review","volume":"19","author":"Gomez","year":"2018","journal-title":"Expet Opin. Pharmacother."},{"issue":"4","key":"10.1016\/j.jpsychires.2023.11.042_bib45","doi-asserted-by":"crossref","first-page":"347","DOI":"10.1001\/jama.2020.22106","article-title":"Balancing the risks and benefits of benzodiazepines","volume":"325","author":"Hirschtritt","year":"2021","journal-title":"JAMA"},{"key":"10.1016\/j.jpsychires.2023.11.042_bib46","doi-asserted-by":"crossref","DOI":"10.3389\/fnsys.2022.1014745","article-title":"Editorial: negative valence systems","volume":"16","author":"Honeycutt","year":"2022","journal-title":"Front. Syst. Neurosci."},{"key":"10.1016\/j.jpsychires.2023.11.042_bib47","article-title":"Benzodiazepines and related drugs in orthopaedics [published online ahead of print, 2022 oct 12]","author":"Hozack","year":"2022","journal-title":"J Bone Joint Surg Am"},{"issue":"7","key":"10.1016\/j.jpsychires.2023.11.042_bib48","doi-asserted-by":"crossref","first-page":"748","DOI":"10.1176\/appi.ajp.2010.09091379","article-title":"Research domain criteria (RDoC): toward a new classification framework for research on mental disorders","volume":"167","author":"Insel","year":"2010","journal-title":"Am. J. Psychiatr."},{"issue":"6","key":"10.1016\/j.jpsychires.2023.11.042_bib49","doi-asserted-by":"crossref","first-page":"468","DOI":"10.1080\/15622975.2020.1836399","article-title":"Practical recommendations for the management of treatment-resistant depression with esketamine nasal spray therapy: basic science, evidence-based knowledge and expert guidance","volume":"22","author":"Kasper","year":"2021","journal-title":"World J. Biol. Psychiatr."},{"issue":"4","key":"10.1016\/j.jpsychires.2023.11.042_bib50","doi-asserted-by":"crossref","first-page":"423","DOI":"10.31887\/DCNS.2011.13.4\/nkoen","article-title":"Pharmacotherapy of anxiety disorders: a critical review","volume":"13","author":"Koen","year":"2011","journal-title":"Dialogues Clin. Neurosci."},{"issue":"10","key":"10.1016\/j.jpsychires.2023.11.042_bib51","doi-asserted-by":"crossref","first-page":"1010","DOI":"10.1002\/phar.2170","article-title":"Association between development of dementia and use of benzodiazepines: a systematic review and meta-analysis","volume":"38","author":"Lucchetta","year":"2018","journal-title":"Pharmacotherapy"},{"issue":"1","key":"10.1016\/j.jpsychires.2023.11.042_bib52","doi-asserted-by":"crossref","first-page":"77","DOI":"10.1007\/s00228-018-2550-1","article-title":"Presentations to the emergency department with non-medical use of benzodiazepines and Z-drugs: profiling and relation to sales data","volume":"75","author":"Lyphout","year":"2019","journal-title":"Eur. J. Clin. Pharmacol."},{"issue":"11","key":"10.1016\/j.jpsychires.2023.11.042_bib53","doi-asserted-by":"crossref","first-page":"1632","DOI":"10.1016\/j.mayocp.2016.07.024","article-title":"Benzodiazepine use in older adults: dangers, management, and alternative therapies","volume":"91","author":"Markota","year":"2016","journal-title":"Mayo Clin. Proc."},{"issue":"4","key":"10.1016\/j.jpsychires.2023.11.042_bib54","doi-asserted-by":"crossref","first-page":"283","DOI":"10.1016\/j.euroneuro.2008.12.004","article-title":"Alprazolam treatment immediately after stress exposure interferes with the normal HPA-stress response and increases vulnerability to subsequent stress in an animal model of PTSD","volume":"19","author":"Matar","year":"2009","journal-title":"Eur. Neuropsychopharmacol"},{"issue":"2","key":"10.1016\/j.jpsychires.2023.11.042_bib55","doi-asserted-by":"crossref","first-page":"97","DOI":"10.1176\/appi.ps.201800321","article-title":"Benzodiazepine use and misuse among adults in the United States","volume":"70","author":"Maust","year":"2019","journal-title":"Psychiatr. Serv."},{"issue":"12","key":"10.1016\/j.jpsychires.2023.11.042_bib56","doi-asserted-by":"crossref","first-page":"1183","DOI":"10.4088\/JCP.v63n1214h","article-title":"Hypnotic medication in the aftermath of trauma","volume":"63","author":"Mellman","year":"2002","journal-title":"J. Clin. Psychiatry"},{"issue":"6","key":"10.1016\/j.jpsychires.2023.11.042_bib57","doi-asserted-by":"crossref","first-page":"1601","DOI":"10.1111\/adb.12457","article-title":"Evidence for GABA-A receptor dysregulation in gambling disorder: correlation with impulsivity","volume":"22","author":"Mick","year":"2017","journal-title":"Addiction Biol."},{"issue":"10","key":"10.1016\/j.jpsychires.2023.11.042_bib58","doi-asserted-by":"crossref","DOI":"10.1001\/jamanetworkopen.2021.31012","article-title":"Trends in the use of benzodiazepines, Z-hypnotics, and serotonergic drugs among US women and men before and during the COVID-19 pandemic","volume":"4","author":"Milani","year":"2021","journal-title":"JAMA Netw. Open"},{"issue":"4319","key":"10.1016\/j.jpsychires.2023.11.042_bib59","doi-asserted-by":"crossref","first-page":"849","DOI":"10.1126\/science.918669","article-title":"Benzodiazepine receptor: demonstration in the central nervous system","volume":"198","author":"M\u00f6hler","year":"1977","journal-title":"Science"},{"issue":"5","key":"10.1016\/j.jpsychires.2023.11.042_bib60","doi-asserted-by":"crossref","first-page":"552","DOI":"10.1017\/S1092852921000481","article-title":"Benzodiazepines in autism spectrum disorder-wise or otherwise?","volume":"27","author":"Naguy","year":"2022","journal-title":"CNS Spectr."},{"issue":"10","key":"10.1016\/j.jpsychires.2023.11.042_bib61","doi-asserted-by":"crossref","first-page":"696","DOI":"10.5694\/mja12.11331","article-title":"The sources of pharmaceuticals for problematic users of benzodiazepines and prescription opioids","volume":"199","author":"Nielsen","year":"2013","journal-title":"Med. J. Aust."},{"issue":"6","key":"10.1016\/j.jpsychires.2023.11.042_bib62","article-title":"Antidepressants plus benzodiazepines for adults with major depression","volume":"6","author":"Ogawa","year":"2019","journal-title":"Cochrane Database Syst. Rev."},{"key":"10.1016\/j.jpsychires.2023.11.042_bib63","doi-asserted-by":"crossref","DOI":"10.3389\/fphar.2021.596375","article-title":"Association of benzodiazepine receptor agonist use with changes in psoriasis severity in adult population: a population-based study","volume":"12","author":"Pan","year":"2021","journal-title":"Front. Pharmacol."},{"issue":"1","key":"10.1016\/j.jpsychires.2023.11.042_bib64","doi-asserted-by":"crossref","first-page":"40","DOI":"10.1055\/a-1492-3293","article-title":"Drug-drug interactions between COVID-19 treatments and antidepressants, mood stabilizers\/anticonvulsants, and benzodiazepines: integrated evidence from 3 databases","volume":"55","author":"Plasencia-Garc\u00eda","year":"2022","journal-title":"Pharmacopsychiatry"},{"issue":"1","key":"10.1016\/j.jpsychires.2023.11.042_bib65","doi-asserted-by":"crossref","first-page":"26","DOI":"10.1186\/s12998-022-00435-3","article-title":"Systematic review of guideline-recommended medications prescribed for treatment of low back pain","volume":"30","author":"Price","year":"2022","journal-title":"Chiropr. Man. Ther."},{"issue":"11","key":"10.1016\/j.jpsychires.2023.11.042_bib66","doi-asserted-by":"crossref","first-page":"1340","DOI":"10.1177\/0269881119859372","article-title":"Selective serotonin reuptake inhibitors and benzodiazepines in panic disorder: a meta-analysis of common side effects in acute treatment","volume":"33","author":"Quagliato","year":"2019","journal-title":"J. Psychopharmacol."},{"key":"10.1016\/j.jpsychires.2023.11.042_bib67","doi-asserted-by":"crossref","first-page":"154","DOI":"10.1016\/j.bbi.2015.08.011","article-title":"GABAergic modulation with classical benzodiazepines prevent stress-induced neuro-immune dysregulation and behavioral alterations","volume":"51","author":"Ramirez","year":"2016","journal-title":"Brain Behav. Immun."},{"issue":"11","key":"10.1016\/j.jpsychires.2023.11.042_bib68","doi-asserted-by":"crossref","first-page":"2531","DOI":"10.1038\/npp.2012.115","article-title":"Differential roles of GABA(A) receptor subtypes in benzodiazepine-induced enhancement of brain-stimulation reward","volume":"37","author":"Reynolds","year":"2012","journal-title":"Neuropsychopharmacology"},{"issue":"7","key":"10.1016\/j.jpsychires.2023.11.042_bib69","doi-asserted-by":"crossref","first-page":"514","DOI":"10.1080\/15622975.2018.1500031","article-title":"Benzodiazepines in anxiety disorders: reassessment of usefulness and safety","volume":"20","author":"Rickels","year":"2019","journal-title":"World J. Biol. Psychiatr."},{"issue":"2","key":"10.1016\/j.jpsychires.2023.11.042_bib70","first-page":"407","article-title":"Low-dose dependence in chronic benzodiazepine users: a preliminary report on 119 patients","volume":"22","author":"Rickels","year":"1986","journal-title":"Psychopharmacol. Bull."},{"issue":"10","key":"10.1016\/j.jpsychires.2023.11.042_bib71","doi-asserted-by":"crossref","first-page":"899","DOI":"10.1001\/archpsyc.1990.01810220015002","article-title":"Long-term therapeutic use of benzodiazepines. I. Effects of abrupt discontinuation [published correction appears in Arch Gen Psychiatry 1991 Jan;48(1):51]","volume":"47","author":"Rickels","year":"1990","journal-title":"Arch. Gen. Psychiatr."},{"issue":"12","key":"10.1016\/j.jpsychires.2023.11.042_bib72","first-page":"1353","article-title":"The translational neural circuitry of anxiety","volume":"90","author":"Robinson","year":"2019","journal-title":"J. Neurol. Neurosurg. Psychiatry"},{"key":"10.1016\/j.jpsychires.2023.11.042_bib73","doi-asserted-by":"crossref","DOI":"10.3389\/fpsyt.2022.873126","article-title":"Anxiety in the medically ill: a systematic review of the literature","volume":"13","author":"Romanazzo","year":"2022","journal-title":"Front. Psychiatr."},{"issue":"12","key":"10.1016\/j.jpsychires.2023.11.042_bib74","doi-asserted-by":"crossref","first-page":"1241","DOI":"10.4088\/JCP.13m08592","article-title":"Do benzodiazepines reduce the effectiveness of exposure therapy for posttraumatic stress disorder?","volume":"74","author":"Rosen","year":"2013","journal-title":"J. Clin. Psychiatry"},{"issue":"6","key":"10.1016\/j.jpsychires.2023.11.042_bib75","doi-asserted-by":"crossref","first-page":"2926","DOI":"10.1111\/bcp.15232","article-title":"Transcranial magnetic stimulation as biomarker of excitability in drug development: a randomized, double-blind, placebo-controlled, cross-over study","volume":"88","author":"Ruijs","year":"2022","journal-title":"Br. J. Clin. Pharmacol."},{"issue":"8","key":"10.1016\/j.jpsychires.2023.11.042_bib76","doi-asserted-by":"crossref","first-page":"1543","DOI":"10.1097\/j.pain.0000000000001241","article-title":"Sources of opioid medication for misuse in older adults: results from a nationally representative survey","volume":"159","author":"Schepis","year":"2018","journal-title":"Pain"},{"issue":"10","key":"10.1016\/j.jpsychires.2023.11.042_bib77","doi-asserted-by":"crossref","first-page":"908","DOI":"10.1001\/archpsyc.1990.01810220024003","article-title":"Long-term therapeutic use of benzodiazepines. II. Effects of gradual taper","volume":"47","author":"Schweizer","year":"1990","journal-title":"Arch. Gen. Psychiatr."},{"issue":"5","key":"10.1016\/j.jpsychires.2023.11.042_bib78","doi-asserted-by":"crossref","first-page":"346","DOI":"10.1016\/j.euroneuro.2009.11.011","article-title":"Outcomes of 1014 naturalistically treated inpatients with major depressive episode","volume":"20","author":"Seem\u00fcller","year":"2010","journal-title":"Eur. Neuropsychopharmacol"},{"issue":"5","key":"10.1016\/j.jpsychires.2023.11.042_bib79","doi-asserted-by":"crossref","first-page":"211","DOI":"10.1097\/YIC.0000000000000276","article-title":"Effectiveness and safety of long-term benzodiazepine use in anxiety disorders: a systematic review and meta-analysis","volume":"34","author":"Shinfuku","year":"2019","journal-title":"Int. Clin. Psychopharmacol."},{"key":"10.1016\/j.jpsychires.2023.11.042_bib80","series-title":"The Rise and Fall of the Age of Psychopharmacology","author":"Shorter","year":"2021"},{"issue":"5","key":"10.1016\/j.jpsychires.2023.11.042_bib81","doi-asserted-by":"crossref","first-page":"304","DOI":"10.1159\/000525208","article-title":"Stigmatization of benzodiazepines: pharmacologic and nonpharmacologic contributions","volume":"91","author":"Silberman","year":"2022","journal-title":"Psychother. Psychosom."},{"key":"10.1016\/j.jpsychires.2023.11.042_bib82","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1016\/j.jsat.2016.06.008","article-title":"Reasons for benzodiazepine use among persons seeking opioid detoxification","volume":"68","author":"Stein","year":"2016","journal-title":"J. Subst. Abuse Treat."},{"key":"10.1016\/j.jpsychires.2023.11.042_bib83","doi-asserted-by":"crossref","first-page":"443","DOI":"10.3389\/fpsyt.2020.00443","article-title":"Pharmacological treatment of anxiety disorders: the role of the HPA Axis","volume":"11","author":"Tafet","year":"2020","journal-title":"Front. Psychiatr."},{"issue":"12","key":"10.1016\/j.jpsychires.2023.11.042_bib84","doi-asserted-by":"crossref","first-page":"3360","DOI":"10.3390\/jcm11123360","article-title":"The association between general anesthesia and new postoperative uses of sedative-hypnotics: a nationwide matched cohort study","volume":"11","author":"Tai","year":"2022","journal-title":"J. Clin. Med."},{"issue":"7","key":"10.1016\/j.jpsychires.2023.11.042_bib85","doi-asserted-by":"crossref","DOI":"10.1016\/j.heliyon.2018.e00688","article-title":"Patterns of benzodiazepines use in primary care adults with anxiety disorders","volume":"4","author":"Tanguay Bernard","year":"2018","journal-title":"Heliyon"},{"issue":"4","key":"10.1016\/j.jpsychires.2023.11.042_bib86","doi-asserted-by":"crossref","first-page":"e124","DOI":"10.1016\/S2542-5196(20)30088-7","article-title":"Adaptive anxiety","volume":"4","year":"2020","journal-title":"Lancet Planet. Health"},{"key":"10.1016\/j.jpsychires.2023.11.042_bib87","series-title":"The Patient Protection and Affordable Care Act of 2010 (P.L. 111-148), as Amended by the Health Care and Education Reconciliation Act of","first-page":"111","year":"2010"},{"issue":"1","key":"10.1016\/j.jpsychires.2023.11.042_bib88","doi-asserted-by":"crossref","first-page":"818","DOI":"10.1186\/s12889-020-08984-z","article-title":"Trends in the consumption rates of benzodiazepines and benzodiazepine-related drugs in the health region of Lleida from 2002 to 2015","volume":"20","author":"Torres-Bondia","year":"2020","journal-title":"BMC Publ. Health"},{"issue":"6 Suppl. 2","key":"10.1016\/j.jpsychires.2023.11.042_bib89","doi-asserted-by":"crossref","first-page":"23S","DOI":"10.1097\/00004714-199912002-00005","article-title":"International study of expert judgment on therapeutic use of benzodiazepines and other psychotherapeutic medications: IV. Therapeutic dose dependence and abuse liability of benzodiazepines in the long-term treatment of anxiety disorders","volume":"19","author":"Uhlenhuth","year":"1999","journal-title":"J. Clin. Psychopharmacol."},{"issue":"4","key":"10.1016\/j.jpsychires.2023.11.042_bib90","doi-asserted-by":"crossref","first-page":"309","DOI":"10.1016\/j.biopsych.2009.08.013","article-title":"Early-life blockade of 5-HT(1A) receptors alters adult anxiety behavior and benzodiazepine sensitivity","volume":"67","author":"Vinkers","year":"2010","journal-title":"Biol. Psychiatr."},{"key":"10.1016\/j.jpsychires.2023.11.042_bib91","doi-asserted-by":"crossref","first-page":"95","DOI":"10.1016\/j.drugalcdep.2019.02.033","article-title":"The epidemiology of benzodiazepine misuse: a systematic review","volume":"200","author":"Votaw","year":"2019","journal-title":"Drug Alcohol Depend."},{"key":"10.1016\/j.jpsychires.2023.11.042_bib92","series-title":"The ICD-10 Classification of Mental and Behavioural Disorders\u2014Diagnostic Criteria for Research","author":"WHO","year":"1993"},{"key":"10.1016\/j.jpsychires.2023.11.042_bib93","series-title":"The ICD-11 Classification of Mental and Behavioural Disorders\u2014Diagnostic Criteria for Research","author":"WHO","year":"2019"},{"issue":"9","key":"10.1016\/j.jpsychires.2023.11.042_bib94","doi-asserted-by":"crossref","first-page":"538","DOI":"10.4140\/TCP.n.2013.538","article-title":"The history of benzodiazepines","volume":"28","author":"Wick","year":"2013","journal-title":"Consult. Pharm."},{"key":"10.1016\/j.jpsychires.2023.11.042_bib95","series-title":"Model List of Essential Medicines","author":"World Health Organization","year":"2011"},{"issue":"6","key":"10.1016\/j.jpsychires.2023.11.042_bib96","doi-asserted-by":"crossref","DOI":"10.1001\/jamanetworkopen.2021.12478","article-title":"Association of new perioperative benzodiazepine use with persistent benzodiazepine use","volume":"4","author":"Wright","year":"2021","journal-title":"JAMA Netw. Open"},{"issue":"7","key":"10.1016\/j.jpsychires.2023.11.042_bib97","doi-asserted-by":"crossref","first-page":"1005","DOI":"10.1016\/j.euroneuro.2013.08.004","article-title":"A proposal for an updated neuropsychopharmacological nomenclature","volume":"24","author":"Zohar","year":"2014","journal-title":"Eur. Neuropsychopharmacol"}],"container-title":["Journal of Psychiatric Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0022395623005575?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0022395623005575?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2024,11,13]],"date-time":"2024-11-13T03:53:43Z","timestamp":1731470023000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0022395623005575"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,2]]},"references-count":97,"alternative-id":["S0022395623005575"],"URL":"https:\/\/doi.org\/10.1016\/j.jpsychires.2023.11.042","relation":{},"ISSN":["0022-3956"],"issn-type":[{"value":"0022-3956","type":"print"}],"subject":[],"published":{"date-parts":[[2024,2]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Revisiting benzodiazepines (GABA Enhancers):A transdiagnostic and precision medicine approach","name":"articletitle","label":"Article Title"},{"value":"Journal of Psychiatric Research","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jpsychires.2023.11.042","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2023 Elsevier Ltd. All rights reserved.","name":"copyright","label":"Copyright"}]}}